Pfizer2011年年报.pdf

PFIZER REPORTS SECOND-QUARTER 2011 RESULTS  Second-Quarter 2011 Revenues of $17.0 Billion, excluding $214 Million from Capsugel(1)  Second-Quarter 2011 Adjusted Diluted EPS(2) of $0.60, excluding Capsugel(1); Reported Diluted EPS(3) of $0.33  Reaffirms Full-Year 2011 Financial Guidance and Full-Year 2012 Financial Targets  Repurchases $2.2 Billion, or 109.2 Million Shares, of Common Stock During Second- Quarter 2011 ($ in millions, except per share amounts) Second-Quarter Year-to-Date 2011 2010 Change 2011 2010 Change Reported Revenues $ 16,984 $ 17,132 (1%) $ 33,486 $ 33,708 (1%) Adjusted Income(2) 4,726 4,927 (4%) 9,534 9,789 (3%) Adjusted Diluted EPS(2) 0.60 0.61 (2%) 1.19 1.21 (2%) Reported Net Income(3) 2,610 2,475 5% 4,832 4,501 7% Reported Diluted EPS(3) 0.33 0.31 6% 0.61 0.56 9% See end of text prior to tables for notes. NEW YORK, N.Y., Tuesday, August 2, 2011 – Pfizer Inc. (NYSE: PFE) today reported financial results for second-quarter 2011. As a result of Pfizer’s decision to sell the Capsugel(1) business, all revenues and expenses related to Capsugel(1) in all periods presented are reflected in a single line, Discontinued operations - net of tax . Additionally, due to the acquisition of King Pharmaceuticals, Inc. (King), legacy King operations are reflected in the 2011 results beginning January 31, 2011, in accordance with Pfizer’s domestic and international reporting periods(4), but are not reflected in the resul